Lower dosing of enteric-coated mycophenolate sodium (myfortic) can achieve target mycophenolic acid exposure rapidly in most chinese renal transplant patients: A pilot study

International Journal of Clinical Practice

Volumn 68, Issue , 2014, Pages 31-37

  Yin, H ^a   Qiu, K ^a   Hu, X P ^a   Li, X B ^a   Wang, W ^a   Liu, L H ^a   Zhang, Xiao Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID;

ADULT; AREA UNDER THE CURVE; AREA UNDER THE MOMENT CURVE; ARTICLE; CHINESE; CLINICAL ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TOLERABILITY; ENTERIC COATED TABLET; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM PLASMA CONCENTRATION; MULTIPLE REGRESSION; PILOT STUDY; POSTOPERATIVE PERIOD; PREDICTION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION;

EID: 85011004481     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12404     Document Type: Article

References (22)

1. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113: 515–24.
2. Knoll GA, MacDonald I, Khan A et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 9: 2381–6.
3. Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on outcomes in renal transplantation. Clin Transplant 2003; 3: 200–5.
4. Sanchez Fructuoso A, Calvo N, Moreno MA et al. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil. Transplant Proc 2007; 7: 2194–6.
5. Reyes H, Hernandez AM, Valverde S et al. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. Pediatr Transplantation 2010; 6: 746–52.
6. Lee S, Shin M, Kim E et al. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. Transplant Proc 2010; 42: 793–6.
7. Cho EK, Han DJ, Kim SC et al. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol 2004; 44: 743–50.
8. Jirasiritham S, Sumethkul V, Mavichak V et al. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. Transplant Proc 2004; 36: 2076–8.
9. Budde K, Bauer S, Hambach P et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007; 7: 888–98.
10. Arns W, Gies M, Choi L et al. Absorption characteristics of EC-MPS-an enteric-coated formulation of mycophenolic sodium. Int J Clin Pharmacol Ther 2006; 44: 375–85.
11. Zicheng Y, Peijun Z, Da X et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol 2006; 62: 446–52.
12. Arns W, Breuer S, Choudhury S et al. Enteric--coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005; 19: 199–206.
13. Bullingham R, Monroe S, Nicholls A et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 336: 315–24.
14. Jiao Z, Zhong JY, Zhang M et al. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol 2007; 1: 27-37.
15. Qiu K, Tian H, Wang W et al. Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients. Chin Med J 2012; 23: 4226–32.
16. Sumethkul V, Na-Bangchang K, Kantachuvesiri S et al. Standard dose enteric-coated mycophenolate sodium (EC-MPS) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. Transplant Proc 2005; 37: 861–3.
17. Capone D, Tarantino G, Kadilli I et al. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving entericcoated mycophenolate sodium (EC-MPS) and cyclosporine. Nephrol Dial Transplant 2011; 26: 3019–25.
18. Sommerer C, Krebs SM, Schaier M et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010; 4: 346–57.
19. Hesselink DA, van Hest RM, Mathot RA et al. Cyclosporin interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987–94.
20. Granger DK. Enteric coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001; 33: 3241–4.
21. Budde K, Glander P, Diekmann F et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004; 5: 1333–45.
22. Tornatore KM, Sudchada P, Wilding GE et al. Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients. J Clin Pharmacol 2013; 3: 285–93.